Alligator Bioscience
Aug 01, 2019
FDA approval for Nubeqa; Biodesix, Immodulon collaborates on Cancer treatment; Cancer asset rights to Alligator Bioscience
Bayer and Orion's Nubeqa gets FDA recommendations for Prostate Cancer The U.S. FDA has given its nod to Nubeqa (darolutamide) for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC). Nubeqa is a steroidal androgen receptor inhibitor (ARi), and its recommendation came afte...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
